On August 31, 2009, Puma Acquisition Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company completed its subsequent tender offer for Medarex, Inc. (“MEDX”)
ComCommon Shares. The merger was subsequently consummated on September 1, 2009. As a result, each existing MEDX Common Share will be converted into the right to receive
$16.00 net cash per share.
This corporate event will be coordinated with the Options Clearing Corporation.
Register for regular updates here and manage your email preferences.